BB-031 for Acute Ischemic Stroke
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 228 (estimated)
- Sponsor
- Basking Biosciences, Inc. · Industry
This trial is looking for adults who have had an acute ischemic stroke within the last 24 hours. Participants will receive either the study drug or a placebo and will be monitored for 90 days.
You may be able to join if
- I have been diagnosed with acute ischemic stroke
- I am 18 years or older
- I have anterior circulation intra-cranial occlusion
- My NIHSS score is greater than 3
- I had stroke symptoms start within the last 24 hours
You may not be able to join if
- I have a large volume ischemic stroke
- I have intracranial hemorrhage on my imaging or a history of it
- I have chronic intracranial occlusion
- I weigh more than 125kg
- I have been given a thrombolytic drug or glycoprotein IIb/IIIa inhibitors
- I have ongoing coagulopathy or a history of high-risk bleeding
- I had a stroke within the last 90 days
- I cannot have a contrast brain perfusion scan with MRI or CT
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThe purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset. Participants will be randomized to receive one dose of either the investigational drug or placebo and will be followed for 90 days. A total of 228 patients are planned in this study.
Loading trial locations…